- Home
- GALT
as 10-06-2025 4:00pm EST
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 232.3M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 367.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $6.55 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LEWIS JOEL | GALT | President and CEO | Sep 12 '25 | Sell | $6.36 | 14,000 | $89,048.40 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Sep 12 '25 | Sell | $6.44 | 8,706 | $56,053.58 | 7,614 |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 months ago
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
GlobeNewswire
5 months ago
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire
6 months ago
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
Zacks
6 months ago
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
GlobeNewswire
6 months ago
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
Simply Wall St.
7 months ago
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership
GlobeNewswire
8 months ago
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial
Argus Research
9 months ago
Daily – Vickers Top Insider Picks for 01/17/2025
Compare GALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.